Kornimate/medical-research-clean huggingface dataset:
effects of online aerobic exercise training and physical activity counseling in juvenile familial mediterranean fever

Conditions: Familial Mediterranean Fever; Exercise; Physical Activity

Summary: the aim of the study is to investigate comparison the effectiveness of online aerobic dance exercises versus physical activity counselling in patients with juvenile familial mediterranean fever.


Eligibility criteria:
inclusion criteria: * to be under colchicine treatment for at least 3 months * being in an attack-free period exclusion criteria: * attack in the last 2 weeks * having any systemic chronic disease except familial mediterranean fever * presence of amyloidosis * having arthritis that may prevent participation in exercise

Keywords: familial mediterranean fever online exercise physical activity counseling aerobic dance
extracorporeal shock wave therapy with a wide focus probe for the treatment of erectile dysfunction

Conditions: Erectile Dysfunction

Summary: low intensity shockwaves (1/10 the ones used in lithotripsy) are delivered to the penile tissue. shockwaves are created by a special generator and are focused using a specially designed shockwave applicator apparatus. the shockwaves are delivered through the applicator covering the corpora cavernosa of the penis. in previous studies the investigators used a medium focused probe and in this study the investigators are evaluating results of this therapy using a wider focus probe in the aim of improving results of treatment.


Eligibility criteria:
inclusion criteria: * ed of more than 6 months * at least 50% unsuccessful to attempt sexual intercourse for 4 times at 4 different days * positive response to pde-5 inhibitors * iief-5 domain score of 12-20 denoting mild to severe ed * non-neurological pathology * stable heterosexual relationship for more than 3 months exclusion criteria: * npt - normal/flat * prior prostatectomy surgery * any cause of ed other than vascular related * any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities * clinically significant chronic hematological disease * cardiovascular conditions that prevent sexual activity * history of heart attack, stroke or life-threatening arrhythmia within the prior 6 months. * cancer within the past 5 years. * anti-androgens, oral or injectable androgens * use of any treatment for ed within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories

Keywords: li-eswt erectile dysfunction ed shock waves therapy
evaluation of using patient specific zirconium dioxide implant versus patient specific titanium implant in treatment of chronic condylar dislocation

Conditions: Recurrent Dislocation of Temporomandibular Joint (Disorder)

Summary: alternate hypothesis that treatment of tempromandibular joint dislocation with zirconium dioxide eminoplasty will be more efficient than using titanium onlays in terms of decreasing maximum inter incisal distance and providing better soft tissue response and post-operative patient satisfaction.


Eligibility criteria:
inclusion criteria: * patient with recurrent dislocation with maximum inter incisal opening over 55mm * long-standing dislocation of the tmj involving both fixation for more than 3 weeks and the failure of manual reduction * failure of conservative strategies such as orientation to self-limit jaw movement and the use of a chin-cap or bandage * both sexes * age between 18 and 48 years. * highly motivated patients. exclusion criteria: * post-menopausal females with osteoporosis * patient with uncontrolled systemic disease * pregnancy * psychological disorders, drug or alcohol dependency * known allergies or sensitivities to dental materials, including zirconia, titanium or general anesthetic agents * inability to return for follow up visits. * refusal of participation from the patient
f-18-omfd-pet for radiotherapy treatment planning and evaluation of early therapy response

Conditions: Brain Tumor

Summary: the purpose of this study is to monitor the amino acid uptake of brain tumors, before and during radiotherapy, with positron emission tomography.


Eligibility criteria:
inclusion criteria: * brain tumor * radiation therapy indicated * written consent exclusion criteria: * pregnancy * mental impairment * drug/alcohol abuse

Keywords: radiotherapy f-18-omfd
isis 2503 in treating patients with metastatic and/or locally recurrent colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: isis 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. purpose: phase ii trial to study the effectiveness of isis 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.

objectives: i. determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with isis 2503, an antisense inhibitor of h-ras. ii. determine the safety profile of this regimen in these patients. outline: this is a multicenter study. patients receive isis 2503 iv continuously for 14 days. courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 14-25 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically proven metastatic and/or locally recurrent adenocarcinoma of the colon or rectum that is not expected to be cured with standard therapy patients who previously underwent definitive surgical resection and subsequently develop metastatic disease should have diagnosis reconfirmed with new histologic or cytologic specimen if: more than 5 years have elapsed since primary surgery or primary tumor was stage i or ii at least 1 measurable lesion (2 cm or more in widest diameter) by ct or mri scan no cns metastases patient characteristics: age: 18 and over performance status: ecog 0 or 1 life expectancy: not specified hematopoietic: absolute neutrophil count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl renal: creatinine no greater than 1.5 mg/dl other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 6 months after study no underlying disease state associated with active bleeding no active infection requiring therapy no second malignancy within the past 5 years except curatively treated nonmelanomatous skin cancer prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for metastatic disease at least 6 months since prior adjuvant chemotherapy with or without radiotherapy endocrine therapy: not specified radiotherapy: prior radiotherapy to nonindicator lesion allowed and recovered see chemotherapy surgery: see disease characteristics other: no concurrent approved cancer therapy or other experimental therapy

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
a trial of pirtobrutinib (loxo-305) plus venetoclax and rituximab (pvr) versus venetoclax and rituximab (vr) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (loxo-305) with vr (arm a) compared to vr alone (arm b) in patients with cll/sll who have been previously treated with at least one prior line of therapy. participation could last up to five years.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cll/sll requiring therapy per iwcll 2018 criteria * previous treatment with at least one line of therapy that may include a covalent bruton's tyrosine kinase (btk) inhibitor * platelets greater than or equal to (≥)50 x 10⁹/liter (l), hemoglobin ≥8 grams/deciliter (g/dl) and absolute neutrophil count ≥1.0 x 10⁹/l * adequate organ function * eastern cooperative oncology group (ecog) performance status 0-2 * estimated creatinine clearance ≥30 milliliters per minute (ml/min) exclusion criteria: * known or suspected richter's transformation at any time preceding enrollment * prior therapy with a non-covalent (reversible) btk inhibitor * patients requiring therapeutic anticoagulation with warfarin or another vitamin k antagonist * current treatment with strong cytochrome p450 (cyp) 3a4 (cyp3a4) inhibitors or inducers * prior therapy with venetoclax * central nervous system (cns) involvement * active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * known human immunodeficiency virus (hiv) infection, regardless of cluster of differentiation 4 (cd4) count * allogeneic stem cell transplantation (sct) or chimeric antigen receptor (car)-t within 60 days * active hepatitis b or hepatitis c * known active cytomegalovirus (cmv) infection * uncontrolled immune thrombocytopenic purpura (itp) or autoimmune hemolytic anemia (aiha) * significant cardiovascular disease * vaccination with a live vaccine within 28 days prior to randomization * patients with the following hypersensitivity: * known hypersensitivity to any component or excipient of pirtobrutinib and venetoclax * prior significant hypersensitivity to rituximab * known allergy to allopurinol and inability to take uric acid lowering agent

Keywords: btki hematologic disease lymphoma, non-hodgkin's lymphoma, b-cell
effectiveness of peer navigation and contingency management on retention in hiv care

Conditions: HIV/AIDS

Summary: consistent treatment with anti-retroviral therapy (art) suppresses viral load (vl), prolonging life and improving quality of life for hiv+ persons. suppressing vl benefits communities by reducing transmission to others. mere availability of art and care, however, is insufficient; the benefits of art depend upon hiv+ persons' continuous visits to the health care provider, regular monitoring and regular delivery of medications, - known as retention in hiv care. in spite of national efforts, up to a quarter of hiv+ persons, especially low-income minorities are out of care. innovative interventions are therefore urgently needed to maximize engagement and retention in hiv care, self-reported adherence, as well as hiv-1 rna viral load suppression. in pursuit of these aims, the proposed study will assess outcomes of the following interventions in comparison to usual care: 1) contingency management (cm) only; 2) peer navigation (pn) only; and 3) a combined approach that integrates both cm and pn (ca) which the investigators hypothesize to be most effective in improving hiv clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. diagnosed hiv+ 2. age 18 years or older 3. english or spanish speaking 4. residence in los angeles county 5. prescribed art in prior 24 months 6. \< 3 visits in prior 12 months or have detectable viral load, as identified in the ryan white casewatch database exclusion criteria: not meeting any of the criteria identified above
writing down goals

Conditions: Musculoskeletal Diseases

Summary: the women's health ipu at ut health austin is happy with having patients write down their goals at their first visit and then tracking those. it would be interesting to study people seeking musculoskeletal specialty care to determine whether asking patients what result of their care would be rated a success helps direct the clinician-patient interaction in a more fruitful direction compared to the usual clinical interaction.

people's stated preferences are often inconsistent with what matters most to them (their values). and they are often based on misconceptions, distress, and less effective cognitive coping strategies. for instance, a person might say "my goal is to have no pain" when that is not possible. or they might say "my goal is to get the shot that fixes this" when there is no such shot. it may go without saying that people want: "to be able to live a normal lifestyle" and "to be able to accomplish most of their goals." in other words, people want to be able to be themselves. they are seeking care because they are not able to be themselves or they are concerned that they may not be able to be themselves. the word health comes from an old german word meaning "whole." one part of good health is correcting or alleviating pathophysiology (e.g. reading glasses). another part of good health is evolving one's inner narrative (e.g. "i'm older now and need glasses to read"). the women's health ipu at ut health austin is happy with having patients write down their goals at their first visit and then tracking those. it would be interesting to study people seeking musculoskeletal specialty care to determine whether asking patients what result of their care would be rated a success helps direct the clinician-patient interaction in a more fruitful direction compared to the usual clinical interaction.

Eligibility criteria:
inclusion criteria: * adult patients (18+) * orthopedic visit exclusion criteria: * patients who are illiterate. * patients who do not speak english.

Keywords: decisional conflict orthopedics
efficacy and safety of orally administered bbt-401-1s in subjects with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this is a randomised, double-blind, placebo-controlled, proof of clinical principle study to explore the efficacy and safety of orally administered bbt-401-1s in subjects with ulcerative colitis.


Eligibility criteria:
inclusion criteria: * male or female, of any race, ≥18 and ≤60 years of age. * have been diagnosed with active uc for ≥3 months prior to day 1, as determined by clinical and endoscopic evidence and documented in a histopathology evaluation. * have a total mayo score ≥6, an endoscopic subscore ≥2, rectal bleeding subscore ≥1, and a stool frequency subscore ≥1, regardless of standard of care history. * able to comprehend and willing to voluntarily sign an icf and to abide by the study restrictions. exclusion criteria: * have received: 1. intravenous corticosteroids, rectally administered corticosteroids, or rectally administered 5-aminosalicylic acid within 3 weeks, or 2. janus kinase (jak) inhibitors within 2 weeks, or 3. cyclosporine, mycophenolate, tacrolimus, or methotrexate within 5 weeks, or 4. anti-tnf-α biologics within 9 weeks, or 5. any other biologics (including ustekinumab and vedolizumab) for the treatment of uc within 12 weeks. * have received orally administered azathioprine or 6-mercaptopurine that has been stable for \<8 weeks. * have received orally administered 5-aminosalicylic acid, sulphasalazine, or low-dose corticosteroids (prednisolone ≤20 mg/day or equivalent) that have been stable for \<5 weeks. * have received any other concomitant medications for uc that have been stable (ie, have not started dosing with a new drug or had a change to their dosing regimen) for \<7 days or 5 half-lives, whichever is longer. * have crohn's disease, indeterminate colitis, ischaemic colitis, fulminant colitis, toxic megacolon, chronic (as determined by the investigator) pancolitis, confined proctitis (distal, ≤15 cm), or symptomatic intestinal stenosis. * have a history of extensive colonic resection (subtotal or total colectomy) or are anticipated to require surgical intervention for uc. * have an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine. * have a positive test for clostridium difficile, or have evidence of treatment for clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to day 1.
functional importance of a powered multifunction wrist protocol

Conditions: Upper Limb Amputation at the Hand; Upper Limb Amputation at the Wrist; Amputation; Amputation; Traumatic, Limb

Summary: the focus of this study is to conduct a clinical study in individuals with transradial amputations to compare function using a 1-dof or 2-dof wrist. all prostheses will be attached to a single dof otto bock hand and controlled using a pattern recognition system equivalent to the coapt system. this study will enable the investigator to quantify the relative functional value of powered wrist flexion during both in-laboratory testing and home use. in addition, the investigators will address the effectiveness of different hand-wrist combinations to enhance patient-centered clinical decision making.

the primary objective of this project is to evaluate the functional importance of a multi function wrist compared to a single degree of freedom wrist. this will be accomplished through in laboratory testing and an 8-week home trial. the first aim will involve in-laboratory functional performance testing with a 1-dof or a 2-dof wrist and a one degree of freedom hand. changes in performance will be assessed with multiple outcome measures that include both quantitative and qualitative testing of prosthesis control and functional performance. the second aim will determine how a 2-dof wrist impacts control and home use of a one degree of freedom hand. subjects will compete an 8 week home based trial. participants will be instructed to complete a written home log of activities and electronic logging usage data will also be collected for each experimental condition. the investigators hypothesize that adding a wrist flexion/extension module to a wrist rotation module and a single-dof terminal device will provide significant improvements in function for transradial amputees.

Eligibility criteria:
inclusion criteria: * ages 18-95 * a unilateral upper limb amputation or absence below the elbow * english speaking exclusion criteria: * significant new injury that would prevent use of a prosthesis: the ability to consistently wear a prosthesis and perform activities of daily living and specific performance tasks is necessary to evaluate the relative benefits of the interventions. * cognitive impairment sufficient to adversely affect understanding of or compliance with study requirements, ability to communicate experiences, or ability to give informed consent: the ability to understand and comply with requirements of the study is essential in order for the study to generate useable, reliable data. the ability to obtain relevant user feedback through questionnaires and informal discussion adds significant value to this study. * significant other comorbidity: any other medical issues or injuries that would preclude completion of the study, use of the prostheses, or that would otherwise prevent acquisition of useable data by researchers

Keywords: transradial amputee
microbiology in obstructive biliary disease

Conditions: Biliary Disease

Summary: patients admitted to hospital due to obstructive biliary disease secondary to benign and malign etiologies, undergoing ercp, will be selected. bile sample will be taken in ercp procedure with sterile technique. its macroscopic appearance will be assessed and biliary culture will be performed.

the sample of biliary aspirate will be assessed as follows. 1. its macroscopic appearance will be analyzed: yellow, black, or purulent. 2. biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of maldi-tof ms mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated vitek system.

Eligibility criteria:
inclusion criteria: * patients with diagnosis or suspicion of biliary obstruction of any cause * any gender * over 18 years of age exclusion criteria: * patients referred and previously treated at another hospital/clinic * previous ercp * pregnancy * patient refusal to enter the study
the impact of home delivery of antiretroviral therapy on virological suppression

Conditions: HIV; Community Health Workers; Antiretroviral Therapy, Highly Active

Summary: home delivery of antiretroviral therapy (art) by community health workers (chws) has the potential to reduce key barriers to art care retention. the aim of this study is to determine whether chw-led home delivery of art for patients who are stable on art combined with facility-based care for those not stable on art is non-inferior to the standard of care (facility-based care for all art patients) in achieving and maintaining virological suppression. the primary endpoint of this trial is the proportion of art patients (regardless of whether they were clinically stable on art at enrollment) who are in viral failure at the end of the study period. the non-inferiority design applies only to this primary endpoint. the margin of non-inferiority was set at a risk ratio (comparing intervention to control) of 1.45. this is a cluster-randomized controlled trial set in dar es salaam. the unit of randomization is a healthcare facility with its surrounding neighborhoods (the 'catchment area'). we matched all 48 healthcare facilities offering art services and having affiliated public-sector chws in dar es salaam into pairs (stratified by district) based on having a similar number of patients currently on art. in each pair, one cluster was randomized to the intervention and one to the control arm. the intervention consists of home visits by chws to provide counseling and deliver art to patients who are stable on art, while the control is the standard of care (facility-based art care and chw home visits at least every three months without art home delivery). in addition, within each study arm, half of the healthcare facilities were randomized to enhanced chw-led nutrition counseling and half to standard counseling.


Eligibility criteria:
inclusion criteria: * having attended one of the participating healthcare facilities for art care during the enrolment period * living in a neighborhood that is in the healthcare facility's catchment area exclusion criteria: * art patients who are pregnant at the time of enrollment * inability to provide written informed consent